Bonesupport Holding

Regulatory Filings • May 17, 2018

BONESUPPORT creates its own US Commercial Platform

Lund, Sweden, 08.45 CET, 17 May 2018 – BONESUPPORTHOLDINGAB (publ) announces today that the current distribution agreement has been terminated and will be replaced by a network of independent distributors and its own commercial organization. This will allow BONESUPPORTto increase its market penetration while creating a stronger platform for current products and future launches in the US market.

"Taking control of our commercial platform in the US is crucial to the execution of our strategy to become a leading global orthobiologics company. We will be able to create a more direct relation with the US customers while better capitalizing the potential of our highly differentiated products, particularly CERAMENTG, which we hope will take to the market in 2021", says Emil Billbäck, CEOof BONESUPPORT.

The company intends to create the optimal US commercial platform by:

• Building its own network of independent distributors driving the sales of the BONESUPPORT's products, to a broad range of orthopedic indications.
• Extend the product offering based on new formulations of CERAMENTas well as synergistic bone graft substitute products.
• Increase the own commercial organization from 12 to 23 persons.

BONESUPPORTwill start selling direct on October 20th 2018.

"CERAMENTGwill be a highly innovative product – the first of its kind in the US market – the recruitment of the FORTIFY IDE study, which will provide data for the PMA application of CERAMENTGin 2020, is running according to plan. Expanding our commercial footprint, establishing direct access with our customers, and bolstering our product offering in the US will allow us to build a strong and increasing foundation in the world's largest market for bone graft substitutes.", comments Patrick O'Donnell, Executive Vice President of Commercial Operations, NorthAmerica.

The Company expects that this decided change in market commercialization eventually will generate higher sales volumes in the US. In the short term, the turnover will be less in the US. This could also lead to that the 2020 targets will be achieved later than previously communicated. We will present updated objectives during Q3 2018 after the initiated strategic review is completed.

Conference Call/Webcast Details

The Company will host a conference call and an online presentation at 09:30 am CETon Thursday 17 May.

The dial-in numbers for the conference call are:

UK: +44 20 3008 9808 SE: +46 85 063 95 49 US: +1 85 5831 5946

Webcast

The presentation will also be webcast and can be accessed from the following web address:

https://tv.streamfabriken.com/2018-05-17-bonesupport-pressconference

Hosts: Emil Billbäck, CEOand Björn Westberg, CFO

For more information contact: BONESUPPORT AB

Emil Billbäck, CEO

+46 (0) 46 286 53 70

Björn Westberg, CFO

+46 (0) 46 286 53 60

ir@bonesupport.com

Citigate Dewe Rogerson

Pip Batty, David Dible, Shabnam Bashir, IsabelleAndrews

+44 (0)20 7282 1022

bonesupport@citigatedewerogerson.com

About BONESUPPORT™

BONESUPPORTis an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs directly into the bone void.

BONESUPPORT's marketed bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER(BVF), CERAMENT® G* and CERAMENT® V* are all based on the Company's novel and proprietary CERAMENTtechnology platform. The Company's products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot.

BONESUPPORT's total sales increased from SEK 62 million in 2015 to SEK 129 million in 2017, representing a compound annual growth rate of 45%.

The Company's research and development is focused on the continuing development and refinement of its CERAMENTtechnology to extend its use into

additional indications by the elution of other drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.

BONESUPPORTis listed on Nasdaq Stockholm and trades under the ticker "BONEX" (ISINcode: SE0009858152). Further information is available at www.bonesupport.com.

*CERAMENTG: Not available in the United States, for investigational use only. CERAMENTV: Not available in the United States

BONESUPPORT™ and CERAMENT® are registered trademarks.

This information is such information as BONESUPPORT HOLDING AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07.45 CET on 17 May 2018.